Effectiveness of lipid-lowering therapy in HIV patients

Current Opinion in HIV and AIDS

Volumn 3, Issue 3, 2008, Pages 240-246

  Martínez, Esteban ^a   Leyes, Pere ^a   Ros, Emilio ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cardiovascular risk; Drug efficacy; HIV infection; LDL cholesterol; Lipid lowering therapy

Indexed keywords

ANTIRETROVIRUS AGENT; ATORVASTATIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NUCLEOSIDE ANALOG; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ABSORPTION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; ISCHEMIC HEART DISEASE; LONG TERM CARE; MONOTHERAPY; MUSCLE DISEASE; PREVENTION AND CONTROL; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 42049105994     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282fb7bb9     Document Type: Review

References (74)

1. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-2982.
2. Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis 2007; 7:787-796. This is an updated general review on the pathogenesis and treatment of HIV-associated dyslipidemia.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
4. Joy T, Keogh HM, Hadigan C, et al. Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS 2007; 21:1591-1600. This interesting study suggested that HIV-infected patients have a high intake of saturated fat contributing to dyslipidemia.
5. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy: results from the DAD study. AIDS 2003; 17:1179-1193.
6. Bakhru A, Erlinger TP. Smoking cessation and cardiovascular disease risk factors: results from the Third National Health and Nutrition Examination Survey. PLoS Med 2005; 2:e160.
7. Bedimo R, Ghurani R, Nsuami M, et al. Lipid abnormalities in HIV/hepatitis C virus-coinfected patients. HIV Medicine 2006; 7:530-536.
8. Cooper CL, Mills E, Angel JB. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. AIDS 2007; 21:71-76. This intriguing article shows a 'protective' effect of hepatitis C on antiretroviral therapy-induced dyslipidemia. Although there appear to be consistent data showing that hepatitis C infection leads to lower plasma lipids, it is not clear if this situation may translate into any clinical benefit.
9. Savè s M, Chêne G, Ducimetiè re P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37:292-298.
10. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506-512.
11. Friis-Møller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
12. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. Important study showed that discontinuous antiretroviral therapy is not only deleterious for HIV-associated morbidity and mortality, but also for cardiovascular disease that increases in relation to a decrease of HDL cholesterol, which in turn is associated with the HIV RNA increase.
13. Dubé MP, Stein JH, Aberg JA, et al., for the Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. Guidelines for the evaluation and management of dyslipidemia inhuman immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613-627.
14. European AIDS Clinical Society. Guidelines on the prevention and management of metabolic diseases in HIV. www.eacs.eu/guide/2_Prevention_and_ Management_of_Metabolic_diseases_in_HIV.pdf. [Accessed 19 December 2007]. These are the first European guidelines on metabolic issues of HIV-infected patients. They will be updated regularly and should be the basis for a consensus in the management of metabolic problems in HIV-infected patients in Europe and probably elsewhere.
15. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
16. Lichtenstein K, Armon C, Buchacz K, et al. HIV Outpatient Study Group. Analysis of cardiovascular risk factors in the HIV Outpatient Study Cohort [abstract]. In: 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver. Alexandria: CROI; 2006. Abstract 735.
17. Law MG, Friis-Møller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006; 7:218-230. This article, based on the DAD Study, suggests that cardiovascular risk in HIV-infected patients may be estimated with conventional tools, such as the Framingham score.
18. Friis-Møller N, Worm SW. Can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools. Clin Infect Dis 2007; 45:1082-1084.
19. Sabin C, Weber R, Fontas E, et al. Underutilization of recommended interventions for prevention of cardiovascular disease in HIV-infected patients with established cardiovascular disease or diabetes [abstract]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles. Alexandria: CROI; 2007. Abstract 816.
20. Visnegarwala F, Maldonado M, Sajja P, et al. Lipid lowering effects of statins and fibrates in the general management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect 2004; 49:283-290.
21. Normén L, Yip B, Montaner J, et al. Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets. HIV Medicine 2007; 8:346-356. This is an overall description of the use of lipid-lowering agents in the HIV-infected population of a geographical area in Canada. This article shows the real life situation concerning lipid-lowering use in HIV-infected patients.
22. Aberg JA, Zackin RA, Brobst SW, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005; 21:757-767.
23. Silverberg M, Leyden W, Horberg M, et al. Lipid lowering therapy responses in HIV-positive and HIV-negative dyslipidemic patients enrolled in a large integrated healthcare delivery system [abstract]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles. Alexandria: CROI; 2007. Abstract 814.
24. Townsend ML, Hollowell SB, Bhalodia J, et al. A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia. Int J STD AIDS 2007; 18:851-855. The results of these two studies consistently confirm that the effectiveness of lipid-lowering therapy in HIV-infected patients is lower than in the general population. The authors provide potential explanations that may lead to future solutions.
25. Glass TR, Weber R, Vernazza PL, et al. Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study. HIV Clin Trials 2007; 8:77-85. This is an interesting analysis of the well known Swiss HIV Cohort Study identifying several factors associated with a lack of effectiveness in therapeutic interventions for dyslipidemia.
26. Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005; 19:1051-1058.
27. Bonnet F, Balestre E, Thiébaut R, et al., for the Groupe d'Epidemiologie clinique du SIDA en Aquitanie. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy: Aquitaine Cohort, France, 1999-2001. HIV Medicine 2004; 5:133-139.
28. Roberts WC. The rule of 5 and the rule of 7 in lipid lowering by statin drugs. Am J Cardiol 1997; 80:106-107.
29. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19:540-556.
30. Davignon J. Beneficial cardiovascular pleitropic effects of statins. Circulation 2004; 109 (Suppl 1):III29-III43.
31. Benesic A, Zilly M, Kluge F, et al. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection 2004; 32: 229-233.
32. Aslangul E, Assoumou KL, Bittar R, et al. A prospective, randomized open label trial comparing the efficacy and safety of rosuvastatin versus pravastatin in HIV-infected subjects receiving ritonavir boosted PI with lipid abnormalities [abstract]. In: 11th European AIDS Conference; 24-27 October 2007; Madrid. Paris: EACS; 2007. Abstract late breaker.
33. Pham PA. HMG CoA reductase inhibitors (statins). HIV Guide. http:// www.hopkins-hivguide.org/drug/lipid-lowering_agents/statins/statins.html? contentInstanceId=20424. [Accessed 19 December 2007].
34. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95:120-122.
35. McGoldrick C, Leen CLS. The management of dyslipidaemias in antiretroviral-treated HIV infection: a systematic review. HIV Medicine 2007; 8:325-334. This is an excellent review on the management of dyslipidemia in HIV-infected patients.
36. Stein J, Merwood MA, Bellehumeur JL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 2004; 147:1-7.
37. Hürlimann D, Chenevard R, Ruschitzka F, et al. Effects of statins on endothelial function and lipid profile in HIV-infected persons receiving protease inhibitor-containing antiretroviral combination therapy: a randomised double blind cross over trial. Heart 2006; 92:110-112.
38. Johns KW, Bennet MT, Bondy GP. Are HIV+ patients resistant to statin therapy? Lipids in Health and Disease 2007; 6:27. This interesting study showed less effectiveness than expected with rosuvastatin therapy in HIV-infected patients. The authors suggest that these patients are resistant to statins and provide a rationale for using combination therapy with fibrates or ezetimibe.
39. Stein EA, Black DM. Lipoprotein changes with statins. Curr Atheroscler Rep 2002; 4:14-18.
40. Vasudevan AR, Jones PH. Effective use of combination lipid therapy. Curr Atheroscler Rep 2006; 8:76-84.
41. Boccara F, Simon T, Lacombe K, et al. Influence of pravastatin on carotid artery structure and function in dyslipidemic HIV-infected patients receiving antiretroviral therapy. AIDS 2006; 20:2395-2398.
42. Del Real G, Jimenez-Baranda S, Mira E, et al. Statins inhibit HIV-1 infection by down-regulating rho activity. J Exp Med 2004; 200:541-547.
43. Giguere JF, Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 2004; 78:12062-12065.
44. Sklar PA, Masur H, Grubb JR, et al. Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy. AIDS 2005; 19:1109-1111.
45. Moncunill G, Negredo E, Bosch L, et al. Evaluation of the anti-HIV activity of statins. AIDS 2005; 19:1697-1700.
46. Waters L, Stebbing J, Jones R, et al. The effect of statins on HIV rebound and blips. J Acquir immune Defic Syndr 2005; 39:637-638.
47. Negredo N, Clotet B, Puig J, et al. The effect of atorvastatin treatment on HIV-1 infected patients interrupting antiretroviral therapy. AIDS 2006; 20:619-621.
48. Mallon PWG, Miller J, Kovacic JC, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men: a randomized, placebo-controlled study. AIDS 2006; 20:1003-1010. This study provided data on a potential influence of pravastatin on body fat and lipoatrophy in HIV-infected patients. Despite the solid data, this is the only study showing such an effect, and further confirmation is needed before recommending the use of pravastatin for treating lipoatrophy in HIV-infected patients.
49. Erol A. The role of fat tissue in the cholesterol lowering and the pleiotropic effects of statins: statins activate the generation of metabolically more capable adipocytes. Med Hypotheses 2005; 64:69-73.
50. Gharakhanian S, Boccara F, Capeau J. Statins in HIV-associated lipodystrophy and metabolic syndrome: is there a missing link. AIDS 2006; 20:1061-1063.
51. Steiner G. Fibrates and coronary risk reduction. Atherosclerosis 2005;182:199-207.
52. Gervois P, Fruchart JC, Staels B. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab 2007; 3:145-156.
53. Fruchart JC. Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. Am J Cardiol 2001; 88:24N-29N.
54. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease - a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007; 154:943-953.
55. Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 2002;30:26-31.
56. Miller J, Brown D, Amin J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridemia. AIDS 2002; 16:2195-2200.
57. Badiou S, Merle De Boever C, Dupuy AM, et al. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004; 172:273-279.
58. Martinez E, Domingo P, Ribera E, et al. Effects of metformin or gemfibrozil on the lypodystrophy of HIV-infected patients receiving protease inhibitors. Antiviral Therapy 2003; 8:403-410.
59. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007; 99 (Suppl):3C-18C.
60. Gavrila A, Hsu W, Tsiodras S, et al. Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin Infect Dis 2005; 40:745-749.
61. Nomén L, Frohlich J, Montaner J, et al. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care 2004; 27:2241-2242.
62. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 2003; 107:3124-3128.
63. Wohl D, Hsue P, Richard S, et al. Ezetimibe's effects on the LDL cholesterol levels of HIV-infected patients receiving HAART [abstract]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles. Alexandria: CROI; 2007. Abstract 39.
64. Coll B, Aragonés G, Parra S, et al. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 2006; 20:1675-1677. Two independent studies showed that ezetimibe monotherapy is well tolerated and effective to reduce LDL cholesterol in HIV-infected patients.
65. Negredo E, Moltó J, Puig J, et al. Ezetimibe, a promisong lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 2006; 20:2159-2164. This study showed that combination therapy of statins with ezetimibe is well tolerated and effective to decrease LDL-cholesterol in patients who failed to attain the LDL cholesterol goal with statin monotherapy.
66. Klibanov OM, Gaughan JP, Tedaldi EM, et al. Ezetimibe combined with low dose statin effectively lowers LDL in protease inhibitor treated patients [abstract]. In: Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney. Geneva: IAS; 2007. Abstract TUPEB076.
67. Bennett MT, Johns KW, Bondy GP. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids in Health and Disease 2007; 6:15. This study showed that combination therapy of statins with ezetimibe is well tolerated and effective to decrease LDL-cholesterol in patients who failed to attain the LDL cholesterol goal with statin monotherapy.
68. Gerber MT, Mondy KE, Yarasheski KE, et al. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis 2004; 39:419-425.
69. Dube MP, Wu JW, Aberg JA, et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidemia in patients with HIV infection: a prospective multicentre study (ACTG 5148) [abstract]. In: Seventh International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 13-16 November 2005; Dublin. London: International Medical Press; 2005. Abstract 12.
70. Hadigan C, Liebau J, Torriani M, et al. Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia. J Clin Endocrinol Metab 2006;91:4438-4444.
71. Baril JG, Kovacs CM, Trottier S, et al. Effectiveness and tolerability of low-dose salmon oil to HIV patients with HAART associated dyslipidemia. HIV Clin Trials 2007; 8:400-411.
72. Gerber JG, Kitch DW, Fichtenbaum CJ, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 2007; 25 Oct [Epub ahead of print].
73. Loignon M, Toma E. L-Carnitine for the treatment of highly active antiretroviral therapy-related hypertriglyceridemia in HIV-infected adults. AIDS 2001;15:1194-1195.
74. Fredriksen J, Ueland T, Dyrøy, et al. Lipid-lowering and anti-inflammatory effects of tetradecylthioacetic acid in HIV-infected patients on highly active antiretroviral therapy. Eur J Clin Invest 2004; 34:709-715.